{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:02:46Z","timestamp":1789398166868,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"State Research Funding for University-level health Research, Kuopio University Hospital, Wellbeing Service County of North Savo","award":["5654210"],"award-info":[{"award-number":["5654210"]}]},{"name":"Cancer Foundation of Finland"},{"name":"Cancer Society of North Savo","award":["20240026"],"award-info":[{"award-number":["20240026"]}]},{"DOI":"10.13039\/100008723","name":"Suomen L\u00e4\u00e4ketieteen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","award":["7074"],"award-info":[{"award-number":["7074"]}],"id":[{"id":"10.13039\/100008723","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Paavo Koistinen Foundation","award":["202300011"],"award-info":[{"award-number":["202300011"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40801-026-00561-x","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T17:40:16Z","timestamp":1782236416000},"page":"353-362","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Long-Term Sequelae and Clinical Workload Resulting from Toxicities of Immune Checkpoint Inhibitor (ICI) Therapy in Patients with Cancer"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1315-2420","authenticated-orcid":false,"given":"Veera","family":"Nurmela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anni","family":"Juntunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satu","family":"Tiainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janne","family":"Martikainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanna","family":"Pasonen-Sepp\u00e4nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aino","family":"R\u00f6nk\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"561_CR1","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1111\/1759-7714.13541","volume":"11","author":"P Song","year":"2020","unstructured":"Song P, Zhang D, Cui X, et al. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients. Thorac Cancer. 2020;11:2406\u201330. https:\/\/doi.org\/10.1111\/1759-7714.13541.","journal-title":"Thorac Cancer"},{"issue":"8","key":"561_CR2","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1080\/14737140.2025.2517274","volume":"25","author":"C Acar","year":"2025","unstructured":"Acar C, Y\u00fcksel H\u00c7, et al. Immune checkpoint inhibitor resumption after discontinuation due to immune-related adverse events: a nomogram-based analysis of risk factors and outcomes. Expert Rev Anticancer Ther. 2025;25(8):983\u201391. https:\/\/doi.org\/10.1080\/14737140.2025.2517274.","journal-title":"Expert Rev Anticancer Ther"},{"key":"561_CR3","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1001\/jamaoncol.2021.1616","volume":"7","author":"JR Patrinely","year":"2021","unstructured":"Patrinely JR, Johnson R, Lawless AR, et al. Chronic immune-related adverse events following adjuvant anti-PD-1 therapy for high-risk resected melanoma. JAMA Oncol. 2021;7:744\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2021.1616.","journal-title":"JAMA Oncol"},{"key":"561_CR4","doi-asserted-by":"publisher","first-page":"e2327145","DOI":"10.1001\/jamanetworkopen.2023.27145","volume":"6","author":"RS Goodman","year":"2023","unstructured":"Goodman RS, Lawless A, Woodford R, et al. Extended follow-up of chronic immune-related adverse events following adjuvant anti-PD-1 therapy for high-risk resected melanoma. JAMA Netw Open. 2023;6:e2327145. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.27145.","journal-title":"JAMA Netw Open"},{"key":"561_CR5","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","volume":"19","author":"DB Johnson","year":"2022","unstructured":"Johnson DB, Nebhan CA, Moslehi JJ, et al. Immune checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022;19:254\u201367. https:\/\/doi.org\/10.1038\/s41571-022-00600-w.","journal-title":"Nat Rev Clin Oncol"},{"key":"561_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008591","volume":"12","author":"K Fletcher","year":"2024","unstructured":"Fletcher K, Johnson DB. Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update. J Immunother Cancer. 2024;12:e008591. https:\/\/doi.org\/10.1136\/jitc-2023-008591.","journal-title":"J Immunother Cancer"},{"key":"561_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006500","volume":"11","author":"CC Barron","year":"2023","unstructured":"Barron CC, Stefanova I, Cha Y, et al. Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review. J Immunother Cancer. 2023;11:e006500. https:\/\/doi.org\/10.1136\/jitc-2022-006500.","journal-title":"J Immunother Cancer"},{"key":"561_CR8","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ejca.2021.03.010","volume":"149","author":"E Ghisoni","year":"2021","unstructured":"Ghisoni E, Wicky A, Bouchaab H, et al. Late-onset and long-lasting immune-related adverse events from immune checkpoint inhibitors: an overlooked aspect in immunotherapy. Eur J Cancer. 2021;149:153\u201364. https:\/\/doi.org\/10.1016\/j.ejca.2021.03.010.","journal-title":"Eur J Cancer"},{"key":"561_CR9","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1217\u201338. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.001.","journal-title":"Ann Oncol"},{"key":"561_CR10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.7861\/clinmed.2018-0440","volume":"20","author":"K Agarwal","year":"2020","unstructured":"Agarwal K, Yousaf N, Morganstein D. Glucocorticoid use and complications following immune checkpoint inhibitor use in melanoma. Clin Med (Lond). 2020;20:163\u20138. https:\/\/doi.org\/10.7861\/clinmed.2018-0440.","journal-title":"Clin Med (Lond)"},{"key":"561_CR11","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ejca.2022.08.029","volume":"176","author":"TU Schulz","year":"2022","unstructured":"Schulz TU, Zierold S, Sachse MM, et al. Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: prevalence and impact on patients\u2019 health-related quality of life. Eur J Cancer. 2022;176:88\u201399. https:\/\/doi.org\/10.1016\/j.ejca.2022.08.029.","journal-title":"Eur J Cancer"},{"key":"561_CR12","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200314","volume":"11","author":"S Rossi","year":"2024","unstructured":"Rossi S, Farina A, Malvaso A, et al. Clinical course of neurologic adverse events associated with immune checkpoint inhibitors: focus on chronic toxicities. Neurol Neuroimmunol Neuroinflamm. 2024;11:e200314. https:\/\/doi.org\/10.1212\/NXI.0000000000200314.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"561_CR13","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.52302","volume":"7","author":"S Cook","year":"2024","unstructured":"Cook S, Samuel V, Meyers DE, et al. Immune-related adverse events and survival among patients with metastatic NSCLC treated with immune checkpoint inhibitors. JAMA Netw Open. 2024;7:e2352302. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.52302.","journal-title":"JAMA Netw Open"},{"key":"561_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CJI.0000000000000300","volume":"43","author":"F Petrelli","year":"2020","unstructured":"Petrelli F, Grizzi G, Ghidini M, et al. Immune-related adverse events and survival in solid tumors treated with immune checkpoint inhibitors: a systematic review and meta-analysis. J Immunother. 2020;43:1\u20137. https:\/\/doi.org\/10.1097\/CJI.0000000000000300.","journal-title":"J Immunother"},{"key":"561_CR15","doi-asserted-by":"publisher","first-page":"7953","DOI":"10.3390\/curroncol29100629","volume":"29","author":"J Tong","year":"2022","unstructured":"Tong J, Kartolo A, Yeung C, et al. Long-term toxicities of immune checkpoint inhibitor in melanoma patients. Curr Oncol. 2022;29:7953\u201363. https:\/\/doi.org\/10.3390\/curroncol29100629.","journal-title":"Curr Oncol"},{"key":"561_CR16","doi-asserted-by":"publisher","first-page":"117955492312104","DOI":"10.1177\/11795549231210475","volume":"17","author":"Q Gui","year":"2023","unstructured":"Gui Q, Xie L, Cheng S, et al. Fast first and then slowly steroid-tapering regimen in managing corticoid-sensitive patients with severe immunotherapy complications after anti-PD-(L)1 therapy for cancer. Clin Med Insights Oncol. 2023;17:11795549231210476. https:\/\/doi.org\/10.1177\/11795549231210475.","journal-title":"Clin Med Insights Oncol"},{"key":"561_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14737140.2026.2614710","volume":"26","author":"C Acar","year":"2026","unstructured":"Acar C, \u015eahin G, Y\u00fcksel H\u00c7, et al. Effect of steroid therapy on survival in patients with metastatic solid tumors experiencing immune-related adverse events. Expert Rev Anticancer Ther. 2026;26:1\u201312. https:\/\/doi.org\/10.1080\/14737140.2026.2614710.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"5","key":"561_CR18","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1080\/1750743X.2025.2492541","volume":"17","author":"V Nurmela","year":"2025","unstructured":"Nurmela V, Juntunen A, Selander T, et al. Poor survival of metastatic cancer patients hospitalized due to immune checkpoint inhibitor-related adverse events. Immunotherapy. 2025;17(5):339\u201346. https:\/\/doi.org\/10.1080\/1750743X.2025.2492541.","journal-title":"Immunotherapy"},{"key":"561_CR19","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/cncr.32542","volume":"126","author":"LX Wang","year":"2020","unstructured":"Wang LX, Quach HT, Moodabigil NV, et al. Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors. Cancer. 2020;126:322\u20138. https:\/\/doi.org\/10.1002\/cncr.32542.","journal-title":"Cancer"},{"key":"561_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7403","volume":"13","author":"A Iaculli","year":"2024","unstructured":"Iaculli A, Ghidini M, Locati F, et al. Multidisciplinary management of immunotherapy-related adverse events in solid tumors: an inter-institutional and telemedicine-based working team. Cancer Med. 2024;13:e7403. https:\/\/doi.org\/10.1002\/cam4.7403.","journal-title":"Cancer Med"},{"issue":"1","key":"561_CR21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12885-025-15460-7","volume":"26","author":"C Acar","year":"2025","unstructured":"Acar C, A\u00e7ar FP, \u015eahin G, et al. Using routine blood tests to predict severe immune-related adverse events during immune checkpoint inhibitor treatment. BMC Cancer. 2025;26(1):83. https:\/\/doi.org\/10.1186\/s12885-025-15460-7.","journal-title":"BMC Cancer"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00561-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-026-00561-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00561-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T14:03:52Z","timestamp":1789394632000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-026-00561-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["561"],"URL":"https:\/\/doi.org\/10.1007\/s40801-026-00561-x","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"1 June 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AR reports personal fees for speaking at symposia or financial support for attending conferences from Amgen, Bristol-Myers Squibb, Merck, Novartis, Pfizer and Roche. ST reports personal fees for speaking at symposia, consulting or financial support for attending conferences from Astra Zeneca, BMS, Merck, MSD, Novartis, Pfizer and Roche. None of the financial support was related to the present study. All other authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The datasets used and\/or analyzed during this study are available from the corresponding author upon reasonable request.","order":2,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki (1964). The study received ethical approval from the Medical Research Ethics Committee of Wellbeing Services County of North Savo (permission number 1482\/2019) and organization-level permission from Kuopio University Hospital (research permit 5654210, 916\/2022). Due to the retrospective nature of the study, the Medical Research Ethics Committee of Wellbeing Services County of North Savo waived the informed consent requirement (permission number 1482\/2019).","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Because of the retrospective design of this study, informed consent was not required.","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors contributed to the study conceptualization and methodology. Investigation, data curation and formal analysis were performed by Veera Nurmela, Anni Juntunen and Aino R\u00f6nk\u00e4. The original draft was written by Veera Nurmela, Anni Juntunen and Aino R\u00f6nk\u00e4. All authors critically reviewed, edited and approved the final manuscript. Project was administrated and supervised by Aino R\u00f6nk\u00e4.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}